Chan Kun-Ming, Lee Wei-Chen
Department of General Surgery and Chang Gung Transplantation Institute, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan; College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Department of General Surgery and Chang Gung Transplantation Institute, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan; College of Medicine, Chang Gung University, Taoyuan, Taiwan.
Biomed J. 2024 Jun 26;48(2):100757. doi: 10.1016/j.bj.2024.100757.
Liver transplantation (LT) is considered the ideal treatment for hepatocellular carcinoma (HCC) concurrent with underlying cirrhotic liver disease. As well-known, LT for HCC based on the Milan criteria has shown satisfactory outcomes. However, numerous expanded transplantation criteria were proposed to benefit more patients for LT and showed comparable survivals as well. In addition, a modest expansion of transplantation criteria for HCC may be acceptable on the basis of the consensus within the transplantation community. Nonetheless, LT in patients with advanced HCC and portal vein tumor thrombosis (PVTT) recently has received attention and has been reported by many transplantation centers despite being contraindicated. Of those, the LT outcomes in certain HCC patients with PVTT were favorable. Additionally, the advancement of multimodality treatments and the evolution of systemic therapies have emerged as promising therapeutic options for downstaging advanced HCC prior to LT. Somehow, advanced HCC with PVTT could be downstaged to become eligible for LT through these multidisciplinary approaches. Although the available evidence of LT for HCC with PVTT is limited, it is hoped that LT may soon be more widely indicated for these patients. Nevertheless, several unknown factors associated with LT for HCC remain to be explored. Herein, this review aimed to update the developments in LT for patients with advanced HCC.
肝移植(LT)被认为是治疗合并潜在肝硬化性肝病的肝细胞癌(HCC)的理想方法。众所周知,基于米兰标准的HCC肝移植已显示出令人满意的结果。然而,为使更多患者受益于肝移植,人们提出了许多扩展移植标准,其生存率也相当。此外,基于移植界的共识,对HCC移植标准进行适度扩展可能是可以接受的。尽管如此,晚期HCC合并门静脉肿瘤血栓形成(PVTT)患者的肝移植最近受到了关注,许多移植中心都有相关报道,尽管这是禁忌证。其中,某些合并PVTT的HCC患者肝移植结果良好。此外,多模式治疗的进展和全身治疗的发展已成为肝移植前降低晚期HCC分期的有前景的治疗选择。通过这些多学科方法,晚期合并PVTT的HCC在某种程度上可以降低分期,从而有资格接受肝移植。虽然HCC合并PVTT肝移植的现有证据有限,但希望肝移植很快能更广泛地应用于这些患者。尽管如此,与HCC肝移植相关的几个未知因素仍有待探索。在此,本综述旨在更新晚期HCC患者肝移植的进展情况。